임상 한눈에 보기

• 9건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 2건 · 완료/종료 7건
• Phase: Phase 1 · Phase 3 · Phase 1, Phase 2 · Phase 2
• Status: Completed · Terminated · Active, not recruiting
• 주요 endpoint: Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs) · Part 1A: Number of Participants With Dose Limiting Toxicity (DLT) · Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters · Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline · Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
• 등록 대상자(표본 합산): 약 1,808명
• 등록된 결과: ORR 18.4%
• 핵심: The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.